Protein / target
P2X purinoceptor 3
Protein at a glance
Biological role
ATP-gated monoatomic cation channel
Strongest disease association
Venous Thrombosis
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Extracellular ATP-activated non-selective cation channel.
View complete UniProt function annotationHide complete annotation
Extracellular ATP-activated non-selective cation channel (PubMed:10440098, PubMed:27626375, PubMed:29674445, PubMed:31232692). Plays particularly important role in sensory neurons where its activation is critical for gustatory, nociceptive responses, visceral reflexes and sensory hypersensitization (By similarity)
Subcellular location
Domains and Gene Ontology detail (18)Hide
Gene Ontology
- Caxon
- Chippocampal mossy fiber to CA3 synapse
- Cplasma membrane
- Cpostsynapse
- Creceptor complex
- CSchaffer collateral - CA1 synapse
- FATP binding
- Fextracellularly ATP-gated monoatomic cation channel activity
- Fmetal ion binding
- Fpurinergic nucleotide receptor activity
- Pcalcium ion transmembrane transport
- Pcellular response to ATP
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·hippocampal mossy fiber to CA3 synapse
- ·postsynapse
- ·Schaffer collateral - CA1 synapse
- ·modulation of chemical synaptic transmission
Ion channel gating
- ·extracellularly ATP-gated monoatomic cation channel activity
- ·calcium ion transmembrane transport
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
P2X purinoceptor 3 antagonist
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene P2RX3
Gene-level evidence surfaced through the gene P2RX3 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
3 compounds recorded · 2 approved · 1 in clinical development
View all recorded compounds (3)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (21)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationGefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial.
- New publicationRandomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain.
- New publicationEfficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial.
- Regulatory approval
Approval: Lyfnua (EMA)
- New publicationThe Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
- New publicationGefapixant in two randomised dose-escalation studies in chronic cough.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.